RAPT Therapeutics Inc. (RAPT)
1.11
-0.03 (-2.63%)
At close: Mar 03, 2025, 12:04 PM
No 1D chart data available
| Bid | 1.11 |
| Market Cap | 146.53M |
| Revenue (ttm) | 17.94M |
| Net Income (ttm) | -364.74M |
| EPS (ttm) | -2.78 |
| PE Ratio (ttm) | -0.4 |
| Forward PE | -0.57 |
| Analyst | Hold |
| Ask | 1.12 |
| Volume | 98,293 |
| Avg. Volume (20D) | 3,508,800 |
| Open | 1.11 |
| Previous Close | 1.14 |
| Day's Range | 1.10 - 1.14 |
| 52-Week Range | 0.79 - 10.05 |
| Beta | 0.03 |
About RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead onco...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 31, 2019
Employees 70
Stock Exchange NASDAQ
Ticker Symbol RAPT
Website https://www.rapt.com
Analyst Forecast
According to 7 analyst ratings, the average rating for RAPT stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 260.36% from the latest price.
Buy 28.57%
Hold 57.14%
Sell 14.29%
2 months ago
+110.81%
RAPT Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
3 months ago
-39.45%
RAPT Therapeutics shares are trading lower after the company terminated its Zelnecirnon program following an FDA clinical hold due to a severe adverse event involving liver injury.
